/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Spyre Therapeutics (SYRE) generated about n/a in revenue and -$179 million in net income over the trailing twelve months, growing at roughly -28.2% a year. Figures are from SEC filings; this is analysis, not investment advice.
Spyre Therapeutics reported about -$179 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Spyre Therapeutics's revenue has compounded at roughly -28.2% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SYRE's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.
Fiscal year ends Dec.